JIANG ZHONG PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.26 CNY | -0.15% |
|
+2.25% | +30.56% |
| 26/04 | Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 25/03 | Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9,012 | 9,006 | 13,011 | 16,987 | - | - |
| Enterprise Value (EV) 1 | 9,012 | 9,006 | 11,680 | 15,713 | 15,912 | 16,092 |
| P/E ratio | 18.1 x | 15.4 x | 18.6 x | 20.8 x | 18.4 x | 16.4 x |
| Yield | - | - | 3.35% | 5.04% | 5.39% | 5.74% |
| Capitalization / Revenue | - | - | 2.96 x | 3.42 x | 3.04 x | 2.69 x |
| EV / Revenue | - | - | 2.66 x | 3.16 x | 2.85 x | 2.55 x |
| EV / EBITDA | - | - | 11.5 x | 15.1 x | 13.6 x | 12.2 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | 3.43 x | 4.1 x | 4.33 x | 4.24 x |
| Nbr of stocks (in thousands) | 6,23,700 | 6,23,282 | 6,23,145 | 6,23,145 | - | - |
| Reference price 2 | 14.45 | 14.45 | 20.88 | 27.26 | 27.26 | 27.26 |
| Announcement Date | 24/03/22 | 12/03/23 | 22/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 4,390 | 4,968 | 5,585 | 6,310 |
| EBITDA 1 | - | - | 1,015 | 1,042 | 1,172 | 1,318 |
| EBIT 1 | - | - | 894.1 | 990.4 | 1,122 | 1,270 |
| Operating Margin | - | - | 20.37% | 19.93% | 20.09% | 20.13% |
| Earnings before Tax (EBT) 1 | - | - | 897.1 | 1,045 | 1,180 | 1,329 |
| Net income 1 | 505.7 | 596.1 | 708.3 | 826.3 | 933.2 | 1,050 |
| Net margin | - | - | 16.13% | 16.63% | 16.71% | 16.64% |
| EPS 2 | 0.8000 | 0.9400 | 1.120 | 1.310 | 1.480 | 1.667 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.7000 | 1.375 | 1.470 | 1.565 |
| Announcement Date | 24/03/22 | 12/03/23 | 22/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2023 Q4 | 2024 Q1 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | 53.86 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS 1 | 0.0800 | 0.1900 | 0.4300 | 0.4400 | 0.3400 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 24/03/22 | 22/03/24 | 26/04/24 | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 1,332 | 1,274 | 1,075 | 895 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 17.8% | 19.1% | 23.5% | 26% |
| ROA (Net income/ Total Assets) | - | - | - | 12.3% | 13.2% | 13.5% |
| Assets 1 | - | - | - | 6,718 | 7,070 | 7,778 |
| Book Value Per Share 2 | - | - | 6.090 | 6.650 | 6.300 | 6.440 |
| Cash Flow per Share 2 | - | - | - | 1.350 | 1.740 | 2.100 |
| Capex 1 | - | - | - | 96 | 76 | 76 |
| Capex / Sales | - | - | - | 1.93% | 1.36% | 1.2% |
| Announcement Date | 24/03/22 | 12/03/23 | 22/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
27.26
CNY
Average target price
31.12
CNY
Spread / Average Target
+14.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.56% | 2.35B | |
| +33.43% | 700B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +15.74% | 236B | |
| +6.52% | 202B | |
| -9.24% | 197B | |
| +4.26% | 161B | |
| -3.54% | 157B |
- Stock Market
- Equities
- 600750 Stock
- Financials Jiang Zhong Pharmaceutical Co.,Ltd